Pdb84 Liver Biopsy - A Bottleneck to Nash Diagnosis

Abstract

L) or LDL-C .300 mg/dL (8 mmol/L) under treatment with statins and/or 1 or both parents having clinically diagnosed FH. For the projection of the estimated prevalence of FH to the population of the Colombian Caribbean, the data of the adult population projections for the Colombian Caribbean of 2015 (general 10,442,134, adults 6,685,734) of the Departamento Administrativo Nacional de Estadisticas (DANE) were used. Results: If we assume that 1 of 5 patients with LDL-C .190 mg/dL (5 mmol/L) may have HF. The prevalence of patients with FH was 0.13% (87/64,667). The prevalence of adults with heterozygous FH (FHHe) was 0.13% (85/64,639). The prevalence of adults with homozygous HF (FHHo) was 0.0015% (1/64,639). Applying these estimates to the general population of Colombian Caribbean in 2015, the estimated number of cases of HF, FHHe and FHHo in the Caribbean Colombian could be approximately 13,574, 8,691 and 140, respectively. Conclusions: The estimated prevalence of FH, FHHe and FHHo in Colombian Caribbean was 1 of 769, 1 of 769 and 2 of 100,000 patients, respectively.

Nonalcoholic steatohepatitis medical patient journey from the perspective of hepatologists, gastroenterologists and patients: a cross-sectional survey

“…Hepatologists and gastroenterologists face a number of challenges in diagnosing and treating NASH. NASH is underdiagnosed [ 22 ]; the current requirement for liver biopsy to diagnose NASH may be a barrier to more frequent NASH diagnosis [ 17 ]. Although a liver biopsy is the reference standard for the diagnosis of NASH [ 1 ], many of the patients in our study (47%) said they did not receive a biopsy to establish their NASH diagnosis.…”

“…Many patients and healthcare professionals (HCPs) are hesitant to use liver biopsies due to costs and associated risks [ 16 ]. The requirement for liver biopsy to confirm diagnosis could be contributing to the under-diagnosis of NASH; liver biopsies are potentially dangerous, resource-intensive, and have limited scalability [ 17 ]. The field is looking to non-invasive tests (NITs) to identify those at most risk, who can then be targeted for therapy or more confidently exclude those who do not need specialty care [ 18 ].…”